- Home
- INMB vs ACET Comparison
INMB vs ACET Comparison
Compare INMB & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- ACET
- Stock Information
- Founded
- INMB 2015
- ACET 1947
- Country
- INMB United States
- ACET United States
- Employees
- INMB N/A
- ACET N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- INMB Health Care
- ACET Health Care
- Exchange
- INMB Nasdaq
- ACET Nasdaq
- Market Cap
- INMB 123.0M
- ACET 110.4M
- IPO Year
- INMB 2019
- ACET N/A
- Fundamental
- Price
- INMB $4.91
- ACET $1.39
- Analyst Decision
- INMB Buy
- ACET Strong Buy
- Analyst Count
- INMB 1
- ACET 4
- Target Price
- INMB $22.00
- ACET $5.67
- AVG Volume (30 Days)
- INMB 295.0K
- ACET 508.7K
- Earning Date
- INMB 10-30-2024
- ACET 11-06-2024
- Dividend Yield
- INMB N/A
- ACET N/A
- EPS Growth
- INMB N/A
- ACET N/A
- EPS
- INMB N/A
- ACET N/A
- Revenue
- INMB $85,000.00
- ACET N/A
- Revenue This Year
- INMB N/A
- ACET N/A
- Revenue Next Year
- INMB N/A
- ACET N/A
- P/E Ratio
- INMB N/A
- ACET N/A
- Revenue Growth
- INMB N/A
- ACET N/A
- 52 Week Low
- INMB $4.81
- ACET $1.05
- 52 Week High
- INMB $14.74
- ACET $3.77
- Technical
- Relative Strength Index (RSI)
- INMB 37.93
- ACET 43.80
- Support Level
- INMB $4.87
- ACET $1.38
- Resistance Level
- INMB $5.23
- ACET $1.45
- Average True Range (ATR)
- INMB 0.27
- ACET 0.08
- MACD
- INMB 0.04
- ACET -0.01
- Stochastic Oscillator
- INMB 17.30
- ACET 31.58
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.